CVRX
$3.08
+$0.06 (2.04%)+2.04%
ClosedLoading chart...
IndexN/A
Market Cap0.08B
Enterprise Value0.16B
Income$-0.01B
Sales$0.01B
EmployeesN/A
P/E-1.52
P/S3.27
P/B4.71
P/C-4.54
EV/EBITDA-3.43
EV/SalesN/A
EPS (ttm)-2.02
EarningsN/A
Gross Margin85.33%
Oper. Margin-90.49%
Profit Margin-94.10%
Volume1.87M
Shs Outstand0.03B
Change4.76%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $51.29M | $39.30M | $22.47M | $13.04M | $6.05M | $6.26M |
| Cost of Revenue | $8.33M | $6.26M | $5.00M | $3.64M | $1.44M | $1.68M |
| Gross Profit | $42.96M | $33.04M | $17.47M | $9.40M | $4.61M | $4.57M |
| Gross Margin | 83.75% | 84.08% | 77.75% | 72.08% | 76.21% | 73.10% |
| Operating Expenses | $102.45M | $76.14M | $60.00M | $35.36M | $16.13M | $14.77M |
| Operating Income | $-59.49M | $-43.10M | $-42.53M | $-25.97M | $-11.51M | $-10.19M |
| Operating Margin | -115.98% | -109.69% | -189.27% | -199.20% | -190.22% | -162.92% |
| Net Income | $-59.97M | $-41.20M | $-41.43M | $-43.08M | $-14.11M | $-14.63M |
| Net Margin | -116.91% | -104.85% | -184.38% | -330.45% | -233.09% | -233.87% |
| EPS (Basic) | $-2.65 | $-1.99 | $-2.02 | $-2.11 | $-0.73 | $-0.76 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $133.41M | $115.23M | $124.94M | $152.55M | $64.78M | $29.11M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $62.36M | $39.28M | $15.76M | $6.59M | $358.01M | $308.15M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $71.06M | $75.95M | $109.18M | $145.96M | $-293.24M | $-279.04M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $71.06M | $75.95M | $109.18M | $145.96M | $-293.24M | $-279.04M |
| Total Liabilities & Stockholders Equity | $133.41M | $115.23M | $124.94M | $152.55M | $64.78M | $29.11M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-59.97M | $-41.20M | $-41.43M | $-43.08M | $-14.11M | $-14.63M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-39.14M | $-39.02M | $-42.68M | $-27.73M | $-16.10M | $-12.79M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
CVRX INVESTIGATION: CVRx, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Possibly Recover LossesGlobeNewswire Inc. CVRx, Inc. (CVRX) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following Revenue Guidance Cut and Sales-Execution DisclosuresGlobeNewswire Inc. CVRx, Inc. Investigated by the Portnoy Law FirmGlobeNewswire Inc. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNXGlobeNewswire Inc. CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the FirmGlobeNewswire Inc. CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with BarostimGlobeNewswire Inc. CVRx to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire Inc. Masimo Surges 8.7%: Is This an Indication of Further Gains?Benzinga
Show 12 more stories
Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the FirmGlobeNewswire Inc. CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsGlobeNewswire Inc. CVRx Announces Appointment of Robert Allen John as Chief Revenue OfficerGlobeNewswire Inc. Strength Seen in Silk Road Medical (SILK): Can Its 24.0% Jump Turn into More Strength?Zacks Investment Research CVRx (CVRX) Stock Jumps 33.9%: Will It Continue to Soar?Zacks Investment Research CVRx to Present at the William Blair 44th Annual Growth Stock ConferenceGlobeNewswire Inc. CVRx Announces Key Senior Leadership Team HiresGlobeNewswire Inc. CVRx Reports First Quarter 2024 Financial and Operating ResultsGlobeNewswire Inc. CVRx's (CVRX) Latest Data Favors Barostim's Long-Term BenefitsZacks Investment Research CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024GlobeNewswire Inc. CVRx announces availability of additional data supporting long-term benefits of BarostimGlobeNewswire Inc. New Strong Buy Stocks for January 30thZacks Investment Research
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Discover more
You may be interested in